Tonix Pharmaceuticals stock halted ahead of FDA approval news
Investing.com - Wells Fargo has lowered its price target on NeuroPace Inc (NASDAQ:NPCE) to $15.00 from $17.00 while maintaining an Overweight rating on the stock. According to InvestingPro data, analyst targets range from $15 to $20, with a Strong Buy consensus recommendation and potential upside of 86%.
The medical device company reported second-quarter sales of $23.5 million, representing 22.1% year-over-year growth and exceeding both Wells Fargo’s estimate of $22.9 million and consensus expectations of $23.1 million. This growth aligns with the company’s impressive 17% revenue CAGR over the past five years, as tracked by InvestingPro.
NeuroPace posted earnings per share of -26 cents, falling short of Wells Fargo’s -17 cents estimate and the consensus forecast of -22 cents, though the company improved its cash burn to -$2.3 million compared to -$4.0 million in the same quarter last year.
Management raised both revenue and gross margin guidance for the year, noting that the third quarter is "off to a good start," and confirmed they remain on track to submit NAUTILUS data to the FDA in the second half of 2025.
Wells Fargo has increased its 2025 revenue estimate for NeuroPace by approximately $1 million to $95.9 million, representing 20.1% year-over-year growth, while raising its gross margin estimate from 74.1% to 75.5% and widening its projected 2025 EPS loss estimate from -$0.53 to -$0.83.
In other recent news, Neuropace Inc. reported its second-quarter 2025 earnings with a notable revenue increase to $23.5 million, marking a 22% growth compared to the same period last year. Despite reporting a larger-than-expected loss per share, the company expressed confidence by raising its full-year revenue guidance to between $94 million and $98 million. This adjustment reflects Neuropace’s belief in its ongoing strategic initiatives. The company’s recent performance has caught the attention of investors, as indicated by the stock’s positive movement in after-hours trading. These developments highlight Neuropace’s current financial trajectory and strategic direction. Investors may find the company’s revised revenue projections particularly significant as they consider future opportunities. Additionally, this earnings report underscores Neuropace’s efforts to enhance its market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.